This measure has amended some existing listings for the Pharmaceutical Benefits Scheme (PBS) and added some new items to the listings from 1 April 2014.
Description of the measure
This measure has amended some existing listings for the Pharmaceutical Benefits Scheme (PBS) and added some new items to the listings from 1 April 2014. The PBS gives Australian residents and eligible overseas visitors access to affordable medicines. The changes include:
- tapentadol hydrochloride – new listing for chronic, severe disabling pain not responding to non-narcotic analgesics
- clobetasol propionate – new listing for the treatment of moderate to severe scalp psoriasis
- plerixafor – new listing for the treatment of certain types of cancer (multiple myeloma or lymphoma)
- betamethasone (as dipropionate) and calcipotriol – amended listing enabling patients to access a greater amount of the gel during an episode or flare up of chronic psoriasis
- panitumumab – amended listing for the treatment of K-RAS wild-type (WT) metastatic colorectal cancer (mCRC) in patients who have failed first-line chemotherapy
- tocilizumab – amended listing for the treatment of active polyarticular course juvenile idiopathic arthritis (JIA) as a single-agent or in combination with methotrexate.
Questions and answers
Who will be affected by this measure?
Eligible Australian residents and overseas visitors will be able to access these medicines under the PBS if prescribed by their health professional. Health professionals including pharmacists, general practitioners, specialists and nurse practitioners will need to be aware of these changes.
Am I eligible for this measure?
The Schedule of Pharmaceutical Benefits has been updated to show the new and amended listings. Health professionals will decide if their patient is eligible. Some of these medicines will require patients to meet particular restriction criteria listed in the Schedule of Pharmaceutical Benefits.
When will this measure start and finish?
The new and amended listings on the Schedule of Pharmaceutical Benefits started on 1 April 2014. This is an ongoing measure.